Basic HTML Version
Molecular Microbiology Research (Online) 2012, Vol.2 No.1 1-9
ISSN 1927-5595
http://mmr.sophiapublisher.com
1
Research Report Open Access
A Comprehensive Review on Pharmacotherapeutics of Bovine Mastitis
Chirag M. Modi , Hitesh B. Patel , H. B. Patel , Shailesh K. Mody
Department of Pharmacology & Toxicology, College of Veterinary Science & Animal Husbandry, Sardarkrushinagar Dantiwada Agricultural University,
Sardarkrushinagar, Gujarat, India
Corresponding authors email:
drgvets@gmail.com;
Authors
Molecular Microbiology Research, 2012, Vol.2, No.1 doi: 10.5376/mmr.2012.02.0001
Received: 29 Oct., 2012
Accepted: 15 Nov., 2012
Published: 25 Dec., 2012
This is an open access article published under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Preferred citation for this article:
Modi et al., 2012, A Comprehensive Review on Pharmacotherapeutics of Bovine Mastitis, Molecular Microbiology Research, Vol.2, No.1 1-9 (doi:
10.5376/mmr.2012.02.0001)
Abstract
In 1926 land has first time reported records of mastitis in India. Mastitis is defined as inflammatory reaction of
parenchyma of mammary gland that can be of infectious, traumatic or toxic nature. Mastitis is one the most prevalent disease of dairy
animals characterized by pathological changes in glandular tissues of udder and physical, chemical and microbiological changes in
milk. More than 100 different microorganisms can cause mastitis, and these vary greatly in the route by which they reach the cow
and the nature of the disease they cause. The disease is most common cause of antimicrobial agent use on dairy farms. In USA one
study has indicated 82% of antibiotic residue violations were related to the treatment of mastitis. In on basis of effects on productivity,
international trade animal warfare and zoonotic risk mastitis was ranked highest above all other infectious diseases such as
salmonellosis, Para tuberculosis and bovine viral diarrheoa. The present paper describes the detailed account of antimicrobial use and
treatment decisions for mastitis in bovine include the return of the cow to normal milk production and composition, prevention of
mortality in peracute cases, elimination of infectious microorganisms, and elimination of practices that may lead to drug residues in
milk or meat.
Keywords
Pharmacotherapeutics; Bovine mastitis; Economic importance
1 Introduction
Mastitis is one the most prevalent disease of dairy
animals characterized by pathological changes in
glandular tissues of udder and physical, chemical and
microbiological changes in milk (Prasad, 2000).
Mastitis is defined as inflammatory reaction of
parenchyma of mammary gland that can be of
infectious, traumatic or toxic nature (International
dairy federation, 1987). The disease is most common
cause of antimicrobial agent use on dairy farms
(Erskine, 2000). In USA one study has indicated 82%
of antibiotic residue violations were related to the
treatment of mastitis (Reneau, 1993). In 1926, land
has first time reported records of mastitis in India. On
basis of effects on productivity, international trade
animal warfare and zoonotic risk mastitis was ranked
highest above all other infectious diseases such as
salmonellosis, Para tuberculosis and bovine viral
diarrheoa (Wells et al., 1998).
Effective and economical mastitis control programs
rely on prevention rather than treatment. Herds
practicing mastitis prevention produce higher quality
milk at less cost than herds that do not. Nonetheless,
therapeutic intervention is an important part of a
control program for bovine mastitis. This describes the
strategies of therapy for bovine mastitis, with an
emphasis on antibacterial and anti-inflammatory
therapy. The concept of administering intramammary
infusions of antiseptic solutions as a treatment for
mastitis caused by infectious agents has been present
for at least a century.
Widespread availability and use of antibacterials in
animal agriculture in the 1950s cultivated the
development of a wide variety of commercial products
for intramammary infusion in the 1960s and 1970s.
Initial successes suggested 75% efficacy (cures) in
both lactating and dry-cow formulations; however,
there has been growing skepticism that in many cases,
therapeutic reality falls short of expectations. Chronic